Molecular phenotypes of colorectal cancer and potential clinical applications

Gastroenterology Report

Volumn 3, Issue 4, 2015, Pages 269-276

  Kocarnik, Jonathan M ^a,b   Shiovitz, Stacey ^a,b   Phipps, Amanda I ^a,b  

^a USA   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

BRAF; Colorectal cancer; CpG island methylator phenotype; Epidemiology; KRAS; Microsatellite instability; Treatment

Indexed keywords

EID: 85015418508     PISSN: None     EISSN: 20520034     Source Type: Journal    
DOI: 10.1093/gastro/gov046     Document Type: Review

References (126)

1. Tsoi KK, Pau CY, WuWKet al. Cigarette smoking and the risk of colorectal cancer: A meta-analysis of prospective cohort studies. Clin Gastroenterol Hepatol 2009;7:682-8, e1-e5.
2. Cheng J, Chen Y, Wang X et al. Meta-analysis of prospective cohort studies of cigarette smoking and the incidence of colon and rectal cancers. Eur J Cancer Prev 2015;24:6-15.
3. Yamauchi M, Lochhead P, Morikawa T et al. Colorectal cancer: A tale of two sides or a continuum? Gut 2012;61:794-7.
4. Yamauchi M, Morikawa T, Kuchiba A et al. Assessment of colorectal cancer molecular features along bowel subsites challenges the conception of distinct dichotomy of proximal vs. distal colorectum. Gut 2012;61:847-54.
5. National Comprehensive Cancer Network. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines(r)) for Colon Cancer (version 20). 2015.
6. Sauer R, Liersch T, Merkel S et al. Preoperative vs. postoperative chemoradiotherapy for locally advanced rectal cancer: Results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol 2012;30:1926-33.
7. O'Connell MJ, Colangelo LH, Beart RW et al. Capecitabine and oxaliplatin in the preoperative multimodality treatment of rectal cancer: Surgical end points from National Surgical Adjuvant Breast and Bowel Project trial R-04. J Clin Oncol 2014;32:1927-34.
8. Andre T, Boni C, Navarro M et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 2009;27:3109-16.
9. Hari DM, Leung AM, Lee JH et al. AJCC Cancer Staging Manual 7th edition criteria for colon cancer: Do the complex modifications improve prognostic assessment? J Am Coll Surg 2013;217:181-90.
10. Tournigand C, Andre T, Bonnetain F et al. Adjuvant therapy with fluorouracil and oxaliplatin in stage II and elderly patients (between ages 70 and 75 years) with colon cancer: Subgroup analyses of the Multicenter International Study of Oxaliplatin, Fluorouracil, and Leucovorin in the Adjuvant Treatment of Colon Cancer trial. J Clin Oncol 2012;30:3353-60.
11. Yothers G, O'Connell MJ, Allegra CJ et al. Oxaliplatin as adjuvant therapy for colon cancer: Updated results of NSABP C-07 trial, including survival and subset analyses. J Clin Oncol 2011;29:3768-74.
12. Guastadisegni C, Colafranceschi M, Ottini L et al. Microsatellite instability as a marker of prognosis and response to therapy: A meta-analysis of colorectal cancer survival data. Eur J Cancer 2010;46:2788-98.
13. Lynch HT and de la Chapelle A. Hereditary colorectal cancer. N Engl J Med 2003;348:919-32.
14. Limsui D, Vierkant RA, Tillmans LS et al. Cigarette smoking and colorectal cancer risk by molecularly defined subtypes. J Natl Cancer Inst 2010;102:1012-22.
15. Poynter JN, Haile RW, Siegmund KD et al. Associations between smoking, alcohol consumption, and colorectal cancer, overall and by tumor microsatellite instability status. Cancer Epidemiol Biomarkers Prev 2009;18:2745-50.
16. Slattery ML, Curtin K, Anderson K et al. Associations between cigarette smoking, lifestyle factors, and microsatellite instability in colon tumors. J Natl Cancer Inst 2000;92:1831-6.
17. Chia VM, Newcomb PA, Bigler J et al. Risk of microsatelliteunstable colorectal cancer is associated jointly with smoking and nonsteroidal anti-inflammatory drug use. Cancer Res 2006;66:6877-83.
18. Campbell PT, Jacobs ET, Ulrich CM et al. Case-control study of overweight, obesity, and colorectal cancer risk, overall and by tumor microsatellite instability status. J Natl Cancer Inst 2010;102:391-400.
19. Laghi L and Malesci A. Microsatellite instability and therapeutic consequences in colorectal cancer. Dig Dis 2012;30:304-9.
20. Sargent DJ, Marsoni S, Monges G et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol 2010;28:3219-26.
21. Sinicrope FA, Mahoney MR, Smyrk TC et al. Prognostic impact of deficient DNA mismatch repair in patients with stage III colon cancer from a randomized trial of FOLFOX-based adjuvant chemotherapy. J Clin Oncol 2013;31:3664-72.
22. Gavin PG, Colangelo LH, Fumagalli D et al. Mutation profiling and microsatellite instability in stage II and III colon cancer: An assessment of their prognostic and oxaliplatin predictive value. Clin Cancer Res 2012;18:6531-41.
23. Bertagnolli MM, Niedzwiecki D, Compton CC et al. Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803. J Clin Oncol 2009;27:1814-21.
24. Van Cutsem E, Labianca R, Bodoky G et al. Randomized phase III trial comparing biweekly infusional fluorouracil/ leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3. J Clin Oncol 2009;27:3117-25.
25. Fallik D, Borrini F, Boige V et al. Microsatellite instability is a predictive factor of the tumor response to irinotecan in patients with advanced colorectal cancer. Cancer Res 2003;63:5738-44.
26. Roth AD, Tejpar S, Delorenzi M et al. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: Results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol 2010;28:466-74.
27. Bird AP. CpG-rich islands and the function of DNA methylation. Nature 1986;321:209-13.
28. Gardiner-Garden M and Frommer M. CpG islands in vertebrate genomes. J Mol Biol 1987;196:261-82.
29. Issa JP. CpG island methylator phenotype in cancer. Nat Rev Cancer 2004;4:988-93.
30. Toyota M, Ahuja N, Ohe-Toyota M et al. CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci USA 1999;96:8681-6.
31. Kane MF, Loda M, Gaida GM et al. Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines. Cancer Res 1997;57:808-11.
32. Cunningham JM, Christensen ER, Tester DJ et al. Hypermethylation of the hMLH1 promoter in colon cancer with microsatellite instability. Cancer Res 1998; 58:3455-60.
33. Hughes LA, Khalid-de Bakker CA, Smits KM et al. The CpG island methylator phenotype in colorectal cancer: Progress and problems. Biochim Biophys Acta 2012;1825:77-85
34. Samowitz WS, Albertsen H, Sweeney C et al. Association of smoking, CpG island methylator phenotype, and V600E BRAF mutations in colon cancer. J Natl Cancer Inst 2006; 98:1731-8.
35. Slattery ML, Curtin K, Sweeney C et al. Diet and lifestyle factor associations with CpG island methylator phenotype and BRAF mutations in colon cancer. Int J Cancer 2007; 120:656-63.
36. Ogino S, Nosho K, Kirkner GJ et al. CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut 2009;58:90-6.
37. Lee S, Cho NY, Choi M et al. Clinicopathological features of CpG island methylator phenotype-positive colorectal cancer and its adverse prognosis in relation to KRAS/BRAF mutation. Pathol Int 2008;58:104-13.
38. Juo YY, Johnston FM, Zhang DY et al. Prognostic value of CpG island methylator phenotype among colorectal cancer patients: A systematic review and meta-analysis. Ann Oncol 2014;25:2314-27.
39. Shiovitz S, Bertagnolli MM, Renfro LA et al. CpG island methylator phenotype is associated with response to adjuvant irinotecan-based therapy for stage III colon cancer. Gastroenterology 2014;147:637-45.
40. Van Rijnsoever M, Elsaleh H, Joseph D et al. CpG island methylator phenotype is an independent predictor of survival benefit from 5-fluorouracil in stage III colorectal cancer. Clin Cancer Res 2003;9:2898-903.
41. Min BH, Bae JM, Lee EJ et al. The CpG island methylator phenotype may confer a survival benefit in patients with stage II or III colorectal carcinomas receiving fluoropyrimidinebased adjuvant chemotherapy. BMC Cancer 2011;11:344.
42. Han SW, Lee HJ, Bae JM et al. Methylation and microsatellite status and recurrence following adjuvant FOLFOX in colorectal cancer. Int J Cancer 2013;132:2209-16.
43. Phipps AI, Buchanan DD, Makar KW et al. BRAF mutation status and survival after colorectal cancer diagnosis according to patient and tumor characteristics. Cancer Epidemiol Biomarkers Prev 2012;21:1792-8.
44. Phipps AI, Buchanan DD, Makar KW et al. KRAS-mutation status in relation to colorectal cancer survival: The joint impact of correlated tumour markers. Br J Cancer 2013;108:1757-64.
45. Ogino S, Meyerhardt JA, Irahara N et al. KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803. Clin Cancer Res 2009;15:7322-9.
46. Samowitz WS, Sweeney C, Herrick J et al. Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers. Cancer Res 2005;65:6063-9.
47. Berg M, Danielsen SA, Ahlquist T et al. DNA sequence profiles of the colorectal cancer critical gene set KRAS-BRAFPIK3CA-PTEN-TP53 related to age at disease onset. PLoS One 2010;5:e13978.
48. Shen L, Toyota M, Kondo Y et al. Integrated genetic and epigenetic analysis identifies three different subclasses of colon cancer. Proc Natl Acad Sci USA 2007;104:18654-9.
49. Rajagopalan H, Bardelli A, Lengauer C et al. Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature 2002;418:934.
50. Ikenoue T, Hikiba Y, Kanai F et al. Functional analysis of mutations within the kinase activation segment of B-Raf in human colorectal tumors. Cancer Res 2003;63:8132-7.
51. Davies H, Bignell GR, Cox C et al. Mutations of the BRAF gene in human cancer. Nature 2002;417:949-54.
52. Bos JL, Fearon ER, Hamilton SR et al. Prevalence of ras gene mutations in human colorectal cancers. Nature 1987; 327:293-7.
53. Rosty C, Young JP, Walsh MD et al. Colorectal carcinomas with KRAS mutation are associated with distinctive morphological and molecular features. Mod Pathol 2013; 26:825-34.
54. Imamura Y, Lochhead P, Yamauchi Met al. Analyses of clinicopathological, molecular, and prognostic associations of KRAS codon 61 and codon 146 mutations in colorectal cancer: Cohort study and literature review. Mol Cancer 2014; 13:135.
55. Weijenberg MP, Aardening PW, de Kok TM et al. Cigarette smoking and KRAS oncogene mutations in sporadic colorectal cancer: Results from the Netherlands Cohort Study. Mutat Res 2008;652:54-64.
56. Slattery ML, Anderson K, Curtin K et al. Lifestyle factors and Ki-ras mutations in colon cancer tumors. Mutat Res 2001;483:73-81.
57. Nosho K, Irahara N, Shima K et al. Comprehensive biostatistical analysis of CpG island methylator phenotype in colorectal cancer using a large population-based sample. PLoS One 2008;3:e3698.
58. Therkildsen C, Bergmann TK, Henrichsen-Schnack T et al. The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis. Acta Oncol 2014;53:852-64.
59. Loupakis F, Cremolini C, Salvatore L et al. FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer. Eur J Cancer 2014;50:57-63.
60. Richman SD, Seymour MT, Chambers P et al. KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: Results from the MRC FOCUS trial. J Clin Oncol 2009;27:5931-7.
61. De Roock W, Claes B, Bernasconi D et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: A retrospective consortium analysis. Lancet Oncol 2010;11:753-62.
62. Falchook GS, Long GV, Kurzrock R et al. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: A phase 1 dose-escalation trial. Lancet 2012;379:1893-901.
63. Douillard JY, Siena S, Cassidy J et al. Final results from PRIME: Randomized phase 3 study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer. Ann Oncol 2014;25:1346-55.
64. Van Cutsem E, Kohne CH, Hitre E et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009;360:1408-17.
65. Bokemeyer C, Bondarenko I, Makhson A et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2009;27:663-71.
66. Lievre A, Bachet JB, Boige V et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008;26:374-9.
67. Amado RG, Wolf M, Peeters M et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008;26: 1626-34.
68. Douillard JY, Oliner KS, Siena S et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 2013;369:1023-34.
69. Heinemann V, von Weikersthal LF, Decker T et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as firstline treatment for patients with metastatic colorectal cancer (FIRE-3): A randomised, open-label, phase 3 trial. Lancet Oncol 2014;15:1065-75.
70. National Comprehensive Cancer Network. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines(r)) for Colon Cancer V.3.2014. http://www.nccn. org. Accessed June 16, 2014.
71. Alberts SR, Sargent DJ, Nair S et al. Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: A randomized trial. JAMA 2012;307:1383-93.
72. Manning BD and Cantley LC. AKT/PKB signaling: navigating downstream. Cell 2007;129:1261-74.
73. Chong ML, Loh M, Thakkar B et al. Phosphatidylinositol-3-kinase pathway aberrations in gastric and colorectal cancer: Meta-analysis, co-occurrence and ethnic variation. Int J Cancer 2014;134:1232-8.
74. Samuels Y and Velculescu VE. Oncogenic mutations of PIK3CA in human cancers. Cell Cycle 2004;3:1221-4.
75. Nosho K, Kawasaki T, Ohnishi M et al. PIK3CA mutation in colorectal cancer: Relationship with genetic and epigenetic alterations. Neoplasia 2008;10:534-41.
76. Liao X, Morikawa T, Lochhead P et al. Prognostic role of PIK3CA mutation in colorectal cancer: Cohort study and literature review. Clin Cancer Res 2012;18:2257-68.
77. Whitehall VL, Rickman C, Bond CE et al. Oncogenic PIK3CA mutations in colorectal cancers and polyps. Int J Cancer 2012;131:813-20.
78. Ogino S, Nosho K, Kirkner GJ et al. PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer. J Clin Oncol 2009;27:1477-84.
79. Velho S, Oliveira C, Ferreira A et al. The prevalence of PIK3CA mutations in gastric and colon cancer. Eur J Cancer 2005; 41:1649-54.
80. Day FL, Jorissen RN, Lipton L et al. PIK3CA and PTEN gene and exon mutation-specific clinicopathological and molecular associations in colorectal cancer. Clin Cancer Res 2013;19:3285-96.
81. Abubaker J, Bavi P, Al-Harbi S et al. Clinicopathological analysis of colorectal cancers with PIK3CA mutations in Middle Eastern population. Oncogene 2008;27:3539-45.
82. Zhu YF, Yu BH, Li DL et al. PI3K expression and PIK3CA mutations are related to colorectal cancer metastases. World J Gastroenterol 2012;18:3745-51.
83. Mao C, Yang ZY, Hu XF et al. PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: A systematic review and meta-analysis. Ann Oncol 2012; 23:1518-25.
84. Phipps AI, Makar KW, Newcomb PA. Descriptive profile of PIK3CA-mutated colorectal cancer in postmenopausal women. Int J Colorectal Dis 2013;28:1637-42.
85. Rodon J, Brana I, Siu LL et al. Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors. Invest New Drugs 2014;32:670-81.
86. Ganesan P, Janku F, Naing A et al. Target-based therapeutic matching in early-phase clinical trials in patients with advanced colorectal cancer and PIK3CA mutations. Mol Cancer Ther 2013;12:2857-63.
87. Liao X, Lochhead P, Nishihara R et al. Aspirin use, tumor PIK3CA mutation, and colorectal cancer survival. N Engl J Med 2012;367:1596-606.
88. Chan AT, Ogino S, Fuchs CS. Aspirin use and survival after diagnosis of colorectal cancer. JAMA 2009;302:649-58.
89. Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012;487:330-7.
90. Briggs S and Tomlinson I. Germline and somatic polymerase epsilon and delta mutations define a new class of hypermutated colorectal and endometrial cancers. J Pathol 2013; 230:148-53.
91. Le DT, Uram JN, Wang H et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 2015;372:2509-20.
92. Shiovitz S and Grady WM. Molecular markers predictive of chemotherapy response in colorectal cancer. Curr Gastroenterol Rep 2015;17:431.
93. Huh JW, Lee JH, Kim HR. Pretreatment expression of 13 molecular markers as a predictor of tumor responses after neoadjuvant chemoradiation in rectal cancer. Ann Surg 2014;259:508-15.
94. Noda E, Maeda K, Inoue T et al. Predictive value of expression of ERCC 1 and GST-p for 5-fluorouracil/ oxaliplatin chemotherapy in advanced colorectal cancer. Hepatogastroenterology 2012;59:130-3.
95. Viguier J, Boige V, Miquel C et al. ERCC1 codon 118 polymorphism is a predictive factor for the tumor response to oxaliplatin/ 5-fluorouracil combination chemotherapy in patients with advanced colorectal cancer. Clin Cancer Res 2005;11:6212-17.
96. Zimmer L, Barlesi F, Martinez-Garcia M et al. Phase I expansion and pharmacodynamic study of the oral MEK inhibitor RO4987655 (CH4987655) in selected patients with advanced cancer with RAS-RAF mutations. Clin Cancer Res 2014;20:4251-61.
97. Bertotti A, Migliardi G, Galimi F et al. A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. Cancer Discov 2011;1:508-23.
98. Migliardi G, Sassi F, Torti D et al. Inhibition of MEK and PI3K/ mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas. Clin Cancer Res 2012;18:2515-25.
99. Dienstmann R, Serpico D, Rodon J et al. Molecular profiling of patients with colorectal cancer and matched targeted therapy in phase I clinical trials. Mol Cancer Ther 2012;11:2062-71.
100. Shimizu T, Tolcher AW, Papadopoulos KP et al. The clinical effect of the dual-targeting strategy involving PI3K/AKT/ mTOR and RAS/MEK/ERK pathways in patients with advanced cancer. Clin Cancer Res 2012;18:2316-25.
101. Jass JR. Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. Histopathology 2007;50:113-30.
102. Snover DC. Update on the serrated pathway to colorectal carcinoma. Hum Pathol 2011;42:1-10.
103. Vogelstein B, Fearon ER, Hamilton SR et al. Genetic alterations during colorectal-tumor development. N Engl J Med 1988;319:525-32.
104. Leggett B and Whitehall V. Role of the serrated pathway in colorectal cancer pathogenesis. Gastroenterology 2010;138: 2088-100.
105. Phipps AI, Limburg PJ, Baron JA et al. Association between molecular subtypes of colorectal cancer and patient survival. Gastroenterology 2015;148:77-87, e2.
106. Samadder NJ, Vierkant RA, Tillmans LS et al. Associations between colorectal cancer molecular markers and pathways with clinicopathologic features in older women. Gastroenterology 2013;145:348-56, e1-2.
107. Bettington M, Walker N, Clouston A et al. The serrated pathway to colorectal carcinoma: Current concepts and challenges. Histopathology 2013;62:367-86.
108. Groff RJ, Nash R, Ahnen DJ. Significance of serrated polyps of the colon. Curr Gastroenterol Rep 2008;10:490-8.
109. Li SC and Burgart L. Histopathology of serrated adenoma, its variants, and differentiation from conventional adenomatous and hyperplastic polyps. Arch Pathol Lab Med 2007; 131:440-5.
110. Burnett-Hartman AN, Newcomb PA, Hutter CM et al. Variation in the association between colorectal cancer susceptibility loci and colorectal polyps by polyp type. Am J Epidemiol 2014;180:223-32.
111. Burnett-Hartman AN, Newcomb PA, Potter JD et al. Genomic aberrations occurring in subsets of serrated colorectal lesions but not conventional adenomas. Cancer Res 2013;73: 2863-72.
112. Burnett-Hartman AN, Passarelli MN, Adams SV et al. Differences in epidemiologic risk factors for colorectal adenomas and serrated polyps by lesion severity and anatomical site. Am J Epidemiol 2013;177:625-37.
113. Zhang B, Shrubsole MJ, Li G et al. Association of genetic variants for colorectal cancer differs by subtypes of polyps in the colorectum. Carcinogenesis 2012;33:2417-23.
114. Minoo P, Zlobec I, Peterson M et al. Characterization of rectal, proximal and distal colon cancers based on clinicopathological, molecular and protein profiles. Int J Oncol 2010;37:707-18.
115. Hemminki K, Santi I, Weires M et al. Tumor location and patient characteristics of colon and rectal adenocarcinomas in relation to survival and TNM classes. BMC Cancer 2010;10:688.
116. Kalady MF, Dejulius KL, Sanchez JA et al. BRAF mutations in colorectal cancer are associated with distinct clinical characteristics and worse prognosis. Dis Colon Rectum 2012;55:128-33.
117. Farina-Sarasqueta A, van Lijnschoten G, Moerland E et al. The BRAF V600E mutation is an independent prognostic factor for survival in stage II and stage III colon cancer patients. Ann Oncol 2010;21:2396-402.
118. Sanchez JA, Krumroy L, Plummer S et al. Genetic and epigenetic classifications define clinical phenotypes and determine patient outcomes in colorectal cancer. Br J Surg 2009;96:1196-204.
119. Imamura Y, Morikawa T, Liao X et al. Specific mutations in KRAS codons 12 and 13, and patient prognosis in 1075 BRAF wild-type colorectal cancers. Clin Cancer Res 2012; 18:4753-63.
120. Arain MA, Sawhney M, Sheikh S et al. CIMP status of interval colon cancers: Another piece to the puzzle. Am J Gastroenterol 2010;105:1189-95.
121. Nishihara R, Wu K, Lochhead P et al. Long-term colorectalcancer incidence and mortality after lower endoscopy. N Engl J Med 2013;369:1095-105.
122. East JE, Saunders BP, Jass JR. Sporadic and syndromic hyperplastic polyps and serrated adenomas of the colon: Classification, molecular genetics, natural history, and clinical management. Gastroenterol Clin North Am 2008;37:25-46.
123. Nagasaka T, Koi M, Kloor M et al. Mutations in both KRAS and BRAF may contribute to the methylator phenotype in colon cancer. Gastroenterology 2008;134:1950-60, e1.
124. Ogino S, Kawasaki T, Kirkner GJ et al. CpG island methylator phenotype-low (CIMP-low) in colorectal cancer: Possible associations with male sex and KRAS mutations. J Mol Diagn 2006;8:582-8.
125. Ogino S, Kawasaki T, Kirkner GJ et al. Molecular correlates with MGMT promoter methylation and silencing support CpG island methylator phenotype-low (CIMP-low) in colorectal cancer. Gut 2007;56:1564-71.
126. Whitehall VL, Walsh MD, Young J et al. Methylation of O-6-methylguanine DNA methyltransferase characterizes a subset of colorectal cancer with low-level DNA microsatellite instability. Cancer Res 2001;61:827-30.